Table of Contents
This IP due diligence case study follows a specialty-pharmaceutical acquirer evaluating a mid-cap biotechnology target whose enterprise value rested almost entirely on two marketed products, and shows how a structured patent and regulatory-exclusivity review turned a headline valuation into a risk-adjusted price the board could actually defend. It is a representative scenario: every market statistic below is a cited public figure, and every deal number is clearly framed as a scenario model output rather than a real client outcome. The point is the method — how disciplined IP due diligence separates the revenue a target reports today from the years of protected revenue an acquirer is really buying.
The Challenge
The target looked like a clean growth story: two approved products, a rising sales curve and a banker’s model that extrapolated the curve out a decade. The acquirer’s corporate-development team had built its offer on that trajectory. What the model did not price was the single question that governs every pharmaceutical valuation — for how many more years can the company legally exclude competitors from each product? A drug’s revenue is only as durable as the patents and regulatory exclusivities that wall it off, and biotech is entering the steepest loss-of-exclusivity (LOE) wave in its history.
The numbers set the stakes. EY estimates roughly US$356 billion of worldwide branded sales are at risk from patent expiration between 2023 and 2028, and industry analysts describe the 2028–2030 cliff as the largest since 2010 — the same event that will strip protection from franchises such as Keytruda, Eliquis and Darzalex.
Single-asset dependence magnifies the danger: Merck’s Keytruda alone generated about $29.5 billion in 2024, roughly 56% of the company’s business, with core US patents expiring in 2028. Our target had the same shape in miniature — most of its value sat in one small molecule whose Orange Book-listed composition patent expired in 2028, and one biologic exposed to biosimilar entry. The acquirer needed to know, before signing, exactly which patents protected which dollars, and when each protection ran out.
Our Approach
We ran the IP due diligence as a sequenced review, each stage narrowing what the next had to examine, so the deal team received a revenue-by-exclusivity map rather than a patent list:
- Revenue-to-patent mapping. We tied each material product to the specific patents and claims that actually cover the marketed form — composition of matter, formulation, method of use and manufacturing process — rather than accepting the target’s patent-count summary. Only claims that read on the commercial product protect the revenue.
- Orange Book and Purple Book exclusivity timeline. For the small molecule we pulled every Orange Book-listed patent and its expiry, plus FDA regulatory exclusivities and any pediatric extension; for the biologic we mapped the 12-year reference-product exclusivity under the BPCIA and the biosimilar landscape in the Purple Book.
- Paragraph IV and biosimilar exposure. We searched for ANDA Paragraph IV certifications and biosimilar filings, tested whether any 30-month Hatch-Waxman stay was live, and modelled the earliest realistic generic and biosimilar entry dates against the listed patent expiries.
- Unlisted patents and freedom to operate. Because process and formulation patents frequently sit outside the Orange Book, we ran a freedom-to-operate sweep for unlisted patents that could either extend the target’s protection or block its own next-generation program.
- Validity and litigation review. We assessed the key patents for inter partes review (IPR) and prior-art risk, and pulled the docket on any pending Paragraph IV litigation that could accelerate or delay LOE.
- Chain of title and encumbrances. We traced assignments, university in-licences, inventorship and any Bayh-Dole march-in or field-of-use limits that could constrain what the acquirer thought it was buying.
What the Research Found
The mapping stage did most of the work, and it did not flatter the banker’s model. The lead small molecule’s Orange Book-listed composition-of-matter patent expired in 2028, exactly at the top of the curve the acquirer had extrapolated for another decade. A second listed formulation patent that appeared to extend protection to the 2030s turned out to be narrow and vulnerable: it was a strong Paragraph IV target, meaning a generic could plausibly clear it years early. In a comparable small-molecule LOE, EY notes a franchise faced nine generic entrants at once — a useful anchor for how fast price and share collapse when the wall comes down.
Two findings cut the other way and mattered just as much. A manufacturing-process patent that never appeared in the Orange Book genuinely complicated cost-effective generic entry, adding real — if not decisive — protection the seller had not been marketing. And a co-invented patent central to the pipeline carried a university in-licence with a field-of-use limit and a march-in clause, plus one assignment gap in the chain of title. None was fatal, but each changed the number: the cliff was earlier than modelled, the formulation patent was softer than claimed, and a slice of the pipeline came with strings attached.
The Outcome
The board approved the acquisition — at a repriced number the diligence had costed. Modelling the 2028 cliff, the Paragraph IV exposure on the formulation patent and the biosimilar timeline against the target’s straight-line projection put roughly 22% of the proposed enterprise value at risk (a scenario figure), and the offer was re-cut to reflect protected rather than reported revenue.
Rather than walk, the acquirer restructured. Part of the price moved into an earn-out contingent on the outcome of the Paragraph IV challenge, specific IP representations and warranties were negotiated to cover the assignment gap and the university licence, and the chain-of-title defect was fixed by confirmatory assignment as a condition to closing. The deal that closed was smaller, better protected and structured so the risks the diligence surfaced sat with the party best able to price them — which is what IP due diligence is for.
What This Means for Similar Matters
- Revenue is only as durable as the exclusivity behind it. Map each product to the patents and FDA exclusivities that actually cover the marketed form, then to their expiry dates — not to the target’s headline patent count.
- The Orange Book is the start, not the end. Listed composition and formulation patents set the visible cliff; unlisted process and manufacturing patents can either extend protection or block your own pipeline, and only an FTO sweep finds them.
- A listed patent is not a strong patent. Test each key claim for Paragraph IV and IPR vulnerability — a formulation patent that reads well on paper can fall years before its stated expiry.
- Biologics play by different rules. BPCIA reference-product exclusivity, the patent dance and biosimilar timelines diverge sharply from small-molecule Hatch-Waxman analysis and must be diligenced separately.
- Chain of title and licence terms move the price. University in-licences, field-of-use limits, Bayh-Dole march-in rights and assignment gaps are cheap to find in diligence and expensive to discover after closing.
What This IP Due Diligence Case Study Shows
The value of this IP due diligence case study is not the specific deal — it is the discipline it models. An acquirer’s biggest biotech risk is rarely a patent that is obviously invalid; it is a valuation that quietly assumes today’s revenue keeps flowing after the patents protecting it expire. The 2028–2030 loss-of-exclusivity wave, with an estimated $356 billion of branded sales exposed between 2023 and 2028, makes that assumption more dangerous than at any point since 2010. Diligence that maps revenue to exclusivity, tests the strength of the patents doing the protecting, and prices the gap between reported and protected revenue is the difference between buying a growth story and buying a cliff.
Why Biotech IP Due Diligence Differs From Standard M&A Diligence
Generic M&A diligence checks that patents exist, are in force and are owned by the seller. Biotech IP due diligence has to go further because the regulatory system is welded to the patent system. Under Hatch-Waxman, a branded small molecule lists its patents in the FDA’s Orange Book; a generic files an Abbreviated New Drug Application with a Paragraph IV certification challenging those patents, and that certification can trigger a 30-month litigation stay that sets the real generic-entry date. Biologics run on a parallel track: the Biologics Price Competition and Innovation Act gives a 12-year reference-product exclusivity and a structured “patent dance” that governs when biosimilars can enter.
Layer on regulatory exclusivities, pediatric extensions and the fact that manufacturing-process patents often sit outside the Orange Book entirely, and the timing of a drug’s cliff becomes a legal-regulatory question that only sector-specific diligence can answer. Price a biotech target on patent expiry dates alone and you will misdate the cliff — usually in the seller’s favour.
Data Sources
The market and patent data referenced above comes from:
- EY — Navigating pharma loss of exclusivity — Estimates US$356 billion of worldwide branded sales at risk from patent expiration 2023–2028; documents rapid generic entry on LOE (e.g., nine generics on a single small-molecule launch).
- Blockbuster Drugs on Patent Cliffs Research Report 2025 (GlobeNewswire) — Describes the 2030 patent cliff as the largest since 2010, naming Keytruda, Eliquis and Darzalex among the exposed blockbusters.
- FDA Orange Book (Approved Drug Products with Therapeutic Equivalence Evaluations) — The official FDA database of small-molecule drug patents and exclusivities that anchors Hatch-Waxman patent listing and Paragraph IV certification.
- Congressional Research Service — Patent Listing in FDA's Orange Book (IF12644) — Explains which patents must be listed in the Orange Book, the 30-month stay, Paragraph IV certifications and recent scrutiny of improper listings.
- FDA Purple Book (Biologics) — Official database of licensed biologics and biosimilars underpinning BPCIA reference-product exclusivity and biosimilar-entry analysis.
- USPTO — Patent Trial and Appeal Board (PTAB) — Forum for inter partes review (IPR) proceedings used to test the validity of a target's key patents during diligence.
Discuss an IP Due Diligence Review
Considering a biotech or pharma acquisition? We map a target’s revenue to the patents and regulatory exclusivities that actually protect it — before you sign.
Discuss an IP Due Diligence Review
Related PerspireIP work: IP due diligence services · our IP due diligence guide · biotechnology & pharma patent landscape.
Frequently Asked Questions
Is this a real client engagement?
No. It is a representative scenario built entirely from public patent, FDA and market data, published to demonstrate our method. The page carries a visible disclosure, and every figure in this IP due diligence case study is either a cited public number or clearly framed as a scenario model output.
What is IP due diligence in a biotech acquisition?
It is the review that establishes how durable a target’s revenue really is — mapping each product to the patents and FDA exclusivities that protect it, dating each expiry, testing patent strength against Paragraph IV and IPR challenges, and checking chain of title. It converts a reported revenue curve into a risk-adjusted, protected-revenue curve an acquirer can price.
What is the patent cliff and why does it change a deal price?
The patent cliff is the point at which a drug’s patents and exclusivities expire and generics or biosimilars enter, collapsing price and share. With an estimated $356 billion of branded sales facing loss of exclusivity between 2023 and 2028, mis-dating a target’s cliff by even two years can overstate value by a large margin, which is why diligence prices the cliff explicitly.
Why does the Orange Book matter so much?
For small molecules the Orange Book lists the patents a generic must address, and a Paragraph IV certification against them can trigger a 30-month stay that sets the real generic-entry date. But process and manufacturing patents often sit outside the Orange Book, so diligence has to look beyond it to date the true cliff and to find hidden protection or blocking patents.
How is diligence on a biologic different from a small molecule?
Biologics are governed by the BPCIA rather than Hatch-Waxman: a 12-year reference-product exclusivity, a structured biosimilar “patent dance,” and the Purple Book instead of the Orange Book. Biosimilar entry timelines and litigation dynamics differ sharply from generic small-molecule analysis and must be diligenced on their own track.
How can IP due diligence change deal structure, not just price?
When diligence surfaces a datable risk — a Paragraph IV challenge, an assignment gap, a licence limit — acquirers often keep the deal but restructure it: earn-outs tied to the challenge outcome, specific IP representations and warranties, IP insurance, or confirmatory assignments as closing conditions, so each risk sits with the party best able to bear it.